DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

Align Technology

Pfizer

You definitely don't want to overlook their growth prospects.

3 Overlooked Healthcare Stocks to Buy Right Now

NVIDIA

Block

Two of them even have connections to the popular cryptocurrency.

3 Stocks to Buy If You've Got the Bitcoin Blues

Exelixis

Teladoc

All three healthcare stocks could have solid growth prospects.

What Investors Should Look for With Exelixis, DermTech, and Teladoc Health

DermTech, Inc. (DMTK) CEO John Dobak on Q1 2021 Results - Earnings Call Transcript

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.26% and 26.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q1 Loss, Tops Revenue Estimates

Shares of DermTech (NASDAQ:DMTK) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 3.77% over the past year to ($0.55), which missed the estimate of ($0.42).

Recap: DermTech Q1 Earnings

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results for the quarter ended March 31, 2021. First Quarter 2021 Highlights Billable sample volume of approximately 9,400 for the first quarter of 2021, a 62% increase compared to approximately 5,800 recorded for the first quarter of 2020 and a 13% sequential increase over the fourth quarter of 2020. Assay rev

DermTech Reports First Quarter 2021 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its management will present at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 p.m. Eastern Time. Interested parties may access the live webcast of the presentation and, for 30 days following the UBS conference, the archived webcast of the presentation through the “Investor Relations” secti

DermTech Management to Present at the UBS Global Healthcare Virtual Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Society for Investigational Dermatology (“SID”) virtual meeting May 3-8, 2021. DermTech's chief scientific officer, Michael Howell, PhD, presented research titled, “Non‑Invasively Stratifying Atopic Dermatitis Patients Based on Inflammatory Genes” during the concurrent Patient-Targeted Rese

DermTech Presents Mini-Symposia at 2021 Society of Investigational Dermatology Virtual Summit

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DermTech, Inc. (DMTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Etsy

Gores Holdings VI, Inc.

The prospects of great returns look really good for these stocks.

3 Stocks I Fully Expect to Double or More Within the Next 5 Years

LA JOLLA, Calif.--(BUSINESS WIRE)--In honor of Melanoma and Skin Cancer Awareness Month, DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by the non-invasive DermTech Smart Sticker™ platform and its melanoma test, the Pigmented Lesion Assay or PLA, is launching the #Stickit2Melanoma campaign, urging the public to get proactive about skin exams. One in five Americans develop skin cancer by the age of 70, and every hour of every day one American dies from mela

DermTech Pledges up to $1 Million to Raise Awareness and Support Accessibility of Skin Exams

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its first quarter 2021 financial results after the market closes on Thursday, May 13, 2021. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and recent highlights. In

DermTech to Announce First Quarter Financial Results on May 13, 2021

DermTech, Inc. (DMTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

DermTech, Inc. (DMTK) Moves 11.1% Higher: Will This Strength Last?

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the Stanford University School of Medicine, led by principal investigator, Kavita Sarin, MD, PhD, on research titled, “A Study of Longitudinal Non-Invasive Cytokine Monitoring in Patients with Hidradenitis Suppurativa.” This collaboration highlights DermTech's commitment to using p

DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)

News that Cigna was covering its new skin cancer patch helped send the stock higher.

Why DermTech Stock Was Climbing Today

Bionano Genomics

Aldeyra Therapeutics

Cyclerion Therapeutics Inc

Sol-Gel Technologies

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) are among the biggest health care movers Tuesday.

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

The stock price of DermTech Inc (NASDAQ: DMTK) increased by over 5% pre-market. This is why it happened.

DMTK Stock: Over 5% Increase Pre-Market Explanation

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the launch of DermTech PLAplusTM, its next generation test for the enhanced early detection of melanoma. PLAplus delivers objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma. The new PLAplus test adds TERT (Telomerase Reverse Transcriptase) promoter DNA dr

DermTech Introduces PLAplus with Improved Sensitivity for Early Detection of Melanoma

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the company has become a member of The Skin Cancer Foundation Corporate Council. The Skin Cancer Foundation is a nonprofit organization with a mission to save and improve lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. The Skin Cancer

DermTech Joins Skin Cancer Foundation Corporate Council

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results from its second economic study of the Pigmented Lesion Assay (“PLA”), a non-invasive genomic test that enhances early melanoma detection. The PLA increases detection of lesions at high risk for melanoma while reducing unnecessary surgical procedures relative to the existing diagnostic pathway of vis

OptumInsight Study Describes Cost Savings of DermTech's Pigmented Lesion Assay in the Management of Melanoma

DermTech Inc: A Compelling Growth Story With Upside

Think long-term with this dermatology company.

Should Investors Be Worried About DermTech's Decline From Its 52-Week Highs?

There are lots of reasons to be excited about DermTech's breakthrough diagnostic technology.

Could DermTech Be a Millionaire-Maker Stock?

DermTech's (DMTK) CEO John Dobak on Q4 2020 Results - Earnings Call Transcript

News for DermTech Inc Stock (DMTK)